Entest Biomedical Inc
Entest Group, Inc. does not have significant operations. It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. The company was formerly known as Entest Biomedical, Inc. and changed its name to Entest Group, Inc. in February 2018. Entest Group, Inc. was founded in 2008 and i… Read more
Entest Biomedical Inc (ETNI) - Total Assets
Latest total assets as of November 2019: $0.00 USD
Based on the latest financial reports, Entest Biomedical Inc (ETNI) holds total assets worth $0.00 USD as of November 2019.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Entest Biomedical Inc - Total Assets Trend (2009–2019)
This chart illustrates how Entest Biomedical Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Entest Biomedical Inc - Asset Composition Analysis
Current Asset Composition (August 2019)
Entest Biomedical Inc's total assets of $0.00 consist of 0.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2019)
This chart illustrates how Entest Biomedical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entest Biomedical Inc's current assets represent 0.0% of total assets in 2019, a decrease from 55.3% in 2009.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2019, down from 0.3% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Entest Biomedical Inc Competitors by Total Assets
Key competitors of Entest Biomedical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Aldel Financial II Inc. Class A Ordinary Shares
NASDAQ:ALDF
|
USA | $239.11 Million |
|
ChampionsGate Acquisition Corp
NASDAQ:CHPGU
|
USA | $76.27 Million |
|
Atlas Resources International Inc
PINK:ALSI
|
USA | $6.96K |
|
Itokk Inc
PINK:IKTO
|
USA | $2.24 Million |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
|
Aloys Inc.
KQ:297570
|
Korea | ₩111.17 Billion |
|
Nh Special Purpose Acquisition 14 Co. Ltd
KQ:319400
|
Korea | ₩255.48 Billion |
Entest Biomedical Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Entest Biomedical Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Entest Biomedical Inc is currently not profitable relative to its asset base.
Entest Biomedical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.22 | 0.02 |
| Quick Ratio | 0.00 | 0.22 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-50.66K | $ -4.28K | $ -754.30K |
Entest Biomedical Inc - Advanced Valuation Insights
This section examines the relationship between Entest Biomedical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -100.0% |
| Total Assets | $0.00 |
| Market Capitalization | $9.83K USD |
Valuation Analysis
Below Book Valuation: The market values Entest Biomedical Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Entest Biomedical Inc's assets decreased by 100.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Entest Biomedical Inc (2009–2019)
The table below shows the annual total assets of Entest Biomedical Inc from 2009 to 2019.
| Year | Total Assets | Change |
|---|---|---|
| 2019-08-31 | $0.00 | -- |
| 2018-08-31 | $9.31K | -97.23% |
| 2017-08-31 | $336.17K | +1308.98% |
| 2016-08-31 | $23.86K | +18.35% |
| 2015-08-31 | $20.16K | +89.23% |
| 2014-08-31 | $10.65K | -80.52% |
| 2013-08-31 | $54.69K | -89.64% |
| 2012-08-31 | $527.83K | -5.07% |
| 2011-08-31 | $555.99K | +552.11% |
| 2010-08-31 | $85.26K | +3.91% |
| 2009-08-31 | $82.05K | -- |